Details of Drug

Drug General Information (ID: D0458)
Drug Name	Dexlansoprazole
Drug Type	Small molecule
Drug Synonymous	dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Kapidex; dexilant; R-(+)-LANSOPRAZOLE; Dexilant Solutab; TAK 390; UNII-UYE4T5I70X; TAK-390; (r)-(+)-lansoprazole; T 168390; UYE4T5I70X; AK170558; TAK-390MR; T-168390; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; Dexlansoprazole (INN/USAN); Kapidex; KS-1075; Lansoprazole Click to Show/Hide
Disease Class	DA22: Gastro-oesophageal reflux disease; DA25: Oesophageal ulcer; DA61: Peptic ulcer; DA60: Gastric ulcer
Therapeutic Class	Proton Pump Inhibitors
Structure
Structure	3D Structure		2D Structure
Formula	C16H14F3N3O2S
InChI	1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
InChIKey	MJIHNNLFOKEZEW-RUZDIDTESA-N
Canonical SMILES	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
External Link
	Pubchem ID	9578005
	CAS Number	138530-94-6
	CHEBI ID	135931
	TTD ID	D06YYD
	INTEDE ID	DR0469

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM002 Affected cellular transport AM004 Affected intra/extra-hepatic metabolism AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects BM005 Altered gastric pH BM010 Transporter inhibition BM017 CYP450 enzyme inhibition BM022 CYP450 enzyme induction BM024 Competitive inhibition of metabolic enzyme BM028 Competitive inhibition of renal tubular secretion BM066 Increased risk of hypomagnesemia BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Dexlansoprazole
Affected gastrointestinal absorption
	Altered gastric pH					Drug Num: 52
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0116		Atazanavir	C38H52N6O7	148192	Major		Inter Info	[1], [2], [3], [4], [5], [6], [7]
D0428		Dasatinib	C22H26ClN7O2S	3062316	Major		Inter Info	[8]
D0008		Acalabrutinib	C26H23N7O2	71226662	Major		Inter Info	[9]
D0409		Dacomitinib	C24H25ClFN5O2	11511120	Major		Inter Info	[2], [10]
D1124		Neratinib	C30H29ClN6O3	9915743	Major		Inter Info	[1], [11]
D1232		Pazopanib	C21H23N7O2S	10113978	Major		Inter Info	[2], [12], [13], [14], [15], [16]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Major		Inter Info	[17]
D1404		Rilpivirine	C22H18N6	6451164	Major		Inter Info	[18]
D1459		Selpercatinib	C29H31N7O3	134436906	Major		Inter Info	[2], [19]
D1686		Velpatasvir	C49H54N8O8	67683363	Major		Inter Info	[2], [20]
D0595		Erlotinib	C22H23N3O4	176870	Major		Inter Info	[1], [2], [21], [22]
D1119		Nelfinavir	C32H45N3O4S	64143	Major		Inter Info	[25], [7]
D0079		Ampicillin	C16H19N3O4S	6249	Moderate		Inter Info	[32], [33]
D0141		Bacampicillin	C21H27N3O7S	441397	Moderate		Inter Info	[47], [48]
D0278		Cefditoren	C19H18N6O5S3	9870843	Moderate		Inter Info	[49]
D0288		Cefpodoxime	C15H17N5O6S2	6335986	Moderate		Inter Info	[47], [50], [51], [48]
D0297		Cefuroxime	C16H16N4O8S	5479529	Moderate		Inter Info	[47], [50], [51], [48]
D0439		Delavirdine	C22H28N6O3S	5625	Moderate		Inter Info	[55]
D0195		Bosutinib	C26H29Cl2N5O3	5328940	Moderate		Inter Info	[57]
D0649		Ferrous fumarate	C4H2FeO4	6433164	Moderate		Inter Info	[59], [60], [36], [32], [30], [33], [61], [40], [62], [63]
D0650		Ferrous gluconate	C12H22FeO14	23616740	Moderate		Inter Info	[59], [60], [36], [32], [30], [33], [61], [40], [62], [63]
D0651		Ferrous sulfate anhydrous	FeO4S	24393	Moderate		Inter Info	[59], [32], [64]
D0849		Iron protein succinylate	NA	NA	Moderate		Inter Info	[59], [60], [36], [32], [30], [33], [61], [40], [62], [63]
D0898		Ledipasvir	C49H54F2N8O6	67505836	Moderate		Inter Info	[1], [2], [66]
D1408		Riociguat	C20H19FN8O2	11304743	Moderate		Inter Info	[72]
D1577		Thyroid, porcine	NA	NA	Moderate		Inter Info	[1], [2], [73]
D0491		Digoxin	C41H64O14	2724385	Moderate		Inter Info	[74], [75], [76], [77], [36], [32], [30], [33], [61], [40], [29]
D0692		Fosamprenavir	C25H36N3O9PS	131536	Moderate		Inter Info	[82]
D0713		Gefitinib	C22H24ClFN4O3	123631	Moderate		Inter Info	[83]
D0799		Indinavir	C36H47N5O4	5362440	Moderate		Inter Info	[87]
D0847		Iron	Fe	23925	Moderate		Inter Info	[59], [32], [64]
D0867		Itraconazole	C35H38Cl2N8O4	55283	Moderate		Inter Info	[88], [89], [90], [91], [92], [36], [32], [30], [33], [61], [40], [93]
D0880		Ketoconazole	C26H28Cl2N4O4	456201	Moderate		Inter Info	[88], [89], [90], [91], [92], [36], [32], [30], [33], [61], [40], [93]
D0894		Lapatinib	C29H26ClFN4O4S	208908	Moderate		Inter Info	[2], [94]
D0925		Levothyroxine	C15H11I4NO4	5819	Moderate		Inter Info	[1], [2], [73]
D0934		Liothyronine	C15H12I3NO4	5920	Moderate		Inter Info	[1], [2], [73]
D0935		Liotrix	C30H21I7N2Na2O8	71371	Moderate		Inter Info	[1], [2], [73]
D1109		Naproxen	C14H14O3	156391	Moderate		Inter Info	[95]
D1315		Posaconazole	C37H42F2N8O4	468595	Moderate		Inter Info	[98], [99], [100], [101], [102], [103], [104], [105], [106], [107]
D0017		Acetylsalicylic acid	C9H8O4	2244	Minor		Inter Info	[109], [110], [111]
D0395		Cyanocobalamin	C63H88CoN14O14P	5311498	Minor		Inter Info	[112], [113], [114], [115], [116]
D0133		Axitinib	C22H18N4OS	6450551	Minor		Inter Info	[117]
D0331		Choline salicylate	C12H19NO4	54686350	Minor		Inter Info	[109], [110], [111]
D1272		Phenyl salicylate	C13H10O3	8361	Minor		Inter Info	[109], [110], [111]
D1328		Prasugrel	C20H20FNO3S	6918456	Minor		Inter Info	[121], [122]
D1377		Raltegravir	C20H21FN6O5	54671008	Minor		Inter Info	[123]
D1701		Vismodegib	C19H14Cl2N2O3S	24776445	Minor		Inter Info	[1], [2], [124]
D0539		Duloxetine	C18H19NOS	60835	Minor		Inter Info	[125]
D0989		Mecobalamin	C63H91CoN13O14P	10898559	Minor		Inter Info	[113], [114], [116]
D1439		Salicylic acid (sodium)	C7H6O3	338	Minor		Inter Info	[109], [110], [111]
D1442		Salsalate	C14H10O5	5161	Minor		Inter Info	[109], [110], [111]
D1681		Vandetanib	C22H24BrFN4O2	3081361	Minor		Inter Info	[1], [2], [12], [126]
Affected cellular transport
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 12
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0087		Anisindione	C16H12O3	2197	Moderate		Inter Info	[34], [35], [36], [37], [38], [30], [39], [33], [40], [41], [42], [43], [44], [45], [46]
D0349		Clarithromycin	C38H69NO13	84029	Moderate		Inter Info	[52], [53], [54]
D0002		Abametapir (topical)	C12H12N2	15664	Moderate		Inter Info	[56]
D0543		Duvelisib	C22H17ClN6O	50905713	Moderate		Inter Info	[58]
D0699		Fostamatinib	C23H26FN6O9P	11671467	Moderate		Inter Info	[65]
D0899		Lefamulin	C28H45NO5S	25185057	Moderate		Inter Info	[67], [68], [69]
D0665		Flibanserin	C20H21F3N4O	6918248	Moderate		Inter Info	[78]
D0667		Fluconazole	C13H12F2N6O	3365	Moderate		Inter Info	[2], [79], [36], [38], [30], [33], [61], [40], [80], [81]
D0793		Imatinib	C29H31N7O	5291	Moderate		Inter Info	[84], [85], [33], [86]
D1198		Oxcarbazepine	C15H12N2O2	34312	Moderate		Inter Info	[1], [97]
D1711		Warfarin	C19H16O4	54678486	Moderate		Inter Info	[34], [35], [36], [37], [38], [30], [39], [33], [40], [41], [42], [43], [44], [45], [46]
D0208		Brivaracetam	C11H20N2O2	9837243	Minor		Inter Info	[2], [118]
	CYP450 enzyme induction					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0958		Lumacaftor	C24H18F2N2O5	16678941	Moderate		Inter Info	[70], [2], [71]
D1400		Rifampicin	C43H58N4O12	135398735	Moderate		Inter Info	[2], [108], [69]
D1502		St. John's Wort	NA	NA	Moderate		Inter Info	[2], [108]
	Competitive inhibition of metabolic enzyme					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1526		Tacrolimus	C44H69NO12	445643	Major		Inter Info	[26], [27], [28]
D0364		Clopidogrel	C16H16ClNO2S	60606	Minor		Inter Info	[38]
Affected excretion pathways
	Competitive inhibition of renal tubular secretion					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1025		Methotrexate	C20H22N8O5	126941	Major		Inter Info	[1], [23], [24]
Pharmacodynamic additive effects
	Increased risk of hypomagnesemia					Drug Num: 38
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0056		Amikacin	C22H43N5O13	37768	Moderate		Inter Info	[29]
D0057		Amikacin (liposome)	C22H43N5O13	37768	Moderate		Inter Info	[30], [31], [29]
D0075		Amphotericin B	C47H73NO17	5280965	Moderate		Inter Info	[29]
D0076		Amphotericin B (cholesteryl sulfate)	C47H73NO17	5280965	Moderate		Inter Info	[30], [31], [29]
D0077		Amphotericin B (lipid complex)	C47H73NO17	5280965	Moderate		Inter Info	[30], [31], [29]
D0078		Amphotericin B (liposomal)	C47H73NO17	5280965	Moderate		Inter Info	[30], [31], [29]
D0158		Bendroflumethiazide	C15H14F3N3O4S2	2315	Moderate		Inter Info	[29]
D0166		Benzthiazide	C15H14ClN3O4S3	2343	Moderate		Inter Info	[29]
D0217		Bumetanide	C17H20N2O5S	2471	Moderate		Inter Info	[29]
D0252		Capreomycin	C50H88N28O15	3000502	Moderate		Inter Info	[29]
D0260		Carboplatin	C6H12N2O4Pt	426756	Moderate		Inter Info	[29]
D0306		Cetuximab	NA	NA	Moderate		Inter Info	[29]
D0321		Chlorothiazide	C7H6ClN3O4S2	2720	Moderate		Inter Info	[29]
D0326		Chlorthalidone	C14H11ClN2O4S	2732	Moderate		Inter Info	[29]
D0344		Cisplatin	Cl2H6N2Pt	5702198	Moderate		Inter Info	[29]
D0402		Cyclosporine	C62H111N11O12	5284373	Moderate		Inter Info	[29]
D1231		Patiromer	NA	NA	Moderate		Inter Info	[29]
D1304		Plazomicin	C25H48N6O10	42613186	Moderate		Inter Info	[29]
D0613		Etacrynic acid	C13H12Cl2O4	3278	Moderate		Inter Info	[30], [31], [29]
D0694		Foscarnet	CH3O5P	3415	Moderate		Inter Info	[29]
D0704		Furosemide	C12H11ClN2O5S	3440	Moderate		Inter Info	[29]
D0718		Gentamicin	C21H43N5O7	3467	Moderate		Inter Info	[29]
D0771		Hydrochlorothiazide	C7H8ClN3O4S2	3639	Moderate		Inter Info	[29]
D0775		Hydroflumethiazide	C8H8F3N3O4S2	3647	Moderate		Inter Info	[29]
D0798		Indapamide	C16H16ClN3O3S	3702	Moderate		Inter Info	[29]
D0876		Kanamycin	C18H36N4O11	6032	Moderate		Inter Info	[29]
D1048		Metolazone	C16H16ClN3O3S	4170	Moderate		Inter Info	[29]
D1120		Neomycin	C23H46N6O13	8378	Moderate		Inter Info	[29]
D1136		Nilotinib	C28H22F3N7O	644241	Moderate		Inter Info	[96]
D1220		Panitumumab	NA	NA	Moderate		Inter Info	[29]
D1228		Paromomycin	C23H45N5O14	165580	Moderate		Inter Info	[29]
D1246		Pentamidine	C19H24N4O2	4735	Moderate		Inter Info	[29]
D1311		Polythiazide	C11H13ClF3N3O4S3	4870	Moderate		Inter Info	[29]
D1507		Streptomycin	C21H39N7O12	19649	Moderate		Inter Info	[29]
D1597		Tobramycin	C18H37N5O9	36294	Moderate		Inter Info	[29]
D1605		Tolevamer	C11H16O3S	58817179	Moderate		Inter Info	[30], [31], [29]
D1611		Torasemide	C16H20N4O3S	41781	Moderate		Inter Info	[30], [31], [29]
D1633		Trichlormethiazide	C8H8Cl3N3O4S2	5560	Moderate		Inter Info	[29]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0929		Linaclotide	C59H79N15O21S6	16158208	Minor		Inter Info	[119], [120]

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Drug interactions. Atazanavir and acid-reducing agents. TreatmentUpdate 18 (2006): 4. [PMID: 17209238]
4	Product Information. Evotaz (atazanavir-cobicistat). Bristol-Myers Squibb, Princeton, NJ.
5	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
6	Ray JE, Marriott D, Bloch MT, McLachlan AJ "Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic." Br J Clin Pharmacol 60 (2005): 291-9. [PMID: 16120068]
7	Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids 14 (2000): 1333-9. [PMID: 10930147]
8	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
9	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
10	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
11	Product Information. Nerlynx (neratinib). Puma Biotechnology, Inc., Los Angeles, CA.
12	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
13	Product Information. Votrient (pazopanib). GlaxoSmithKline, Research Triangle Park, NC.
14	Tan AR, Gibbon DG, Stein MN, et al. "Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors." Cancer Chemother Pharmacol 71 (2013): 1635-43. [PMID: 23636448]
15	van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG "Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective." Lancet Oncol 15 (2014): e315-e326. [PMID: 24988935]
16	Yu G, Zheng QS, Wang DX, Zhou HH, Li GF "Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye." Lancet Oncol 15 (2014): e469-70. [PMID: 25281461]
17	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
18	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
19	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
20	Product Information. Epclusa (sofosbuvir-velpatasvir). Gilead Sciences, Foster City, CA.
21	Duong S, Leung M "Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents." J Oncol Pharm Pract 17 (2011): 448-52. [PMID: 20716581]
22	Product Information. Tarceva (erlotinib). Genentech, South San Francisco, CA.
23	Breedveld P, Zelcer N, Pluim D, et.al "Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions." Cancer Res 64 (2004): 5804-11.[PMID: 15313923]
24	Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J "Potential interaction between methotrexate and omeprazole/." Ann Pharmacother 34 (2000): 1024-7.[PMID: 10981249]
25	Product Information. Viracept (nelfinavir). Agouron Pharma Inc, La Jolla, CA.
26	Itagaki F, Homma M, Yuzawa K, et al "Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations." J Pharm Pharmacol 56 (2004): 1055-9. [PMID: 15285851]
27	Lorf T, Ramadori G, Ringe B, Schworer H "The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients." Eur J Clin Pharmacol 56 (2000): 439-40. [PMID: 11009056]
28	Miura M, Inoue K, Kagaya H, et al. "Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients." Biopharm Drug Dispos 28 (2007): 167-75. [PMID: 17377957]
29	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
30	Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
31	Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
32	Product Information. Kapidex (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
33	Product Information. Prevacid (lansoprazole). TAP Pharmaceuticals Inc, Deerfield, IL.
34	Ahmad S "Omeprazole-warfarin interaction." South Med J 84 (1991): 674-5. [PMID: 2035104]
35	Andersson T, HassanAlin M, Hasselgren G, Rohss K "Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole." Clin Pharmacokinet 40 (2001): 523-37. [PMID: 11510629]
36	Product Information. Aciphex (rabeprazole) Janssen Pharmaceuticals, Titusville, NJ.
37	Product Information. Coumadin (warfarin). DuPont Pharmaceuticals, Wilmington, DE.
38	Product Information. Dexilant (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
39	Product Information. Omeprazole (omeprazole). Mylan Pharmaceuticals Inc, Morgantown, WV.
40	Product Information. Protonix (pantoprazole) Wyeth-Ayerst Laboratories, Philadelphia, PA.
41	Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW "Lack of pantoprazole drug interactions in man." Int J Clin Pharmacol Ther 32 (1994): 385-99. [PMID: 7981922]
42	Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW "Lack of pantoprazole drug interactions in man: an updated review." Int J Clin Pharmacol Ther 34 (1 suppl) (1996): s31-50. [PMID: 8793602]
43	Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW "Lack of pantoprazole drug interactions in man: an updated review." Int J Clin Pharmacol Ther 34 (1996): 243-62. [PMID: 8793611]
44	Sutfin T, Blamer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O "Stereoselective interaction of omeprazole with warfarin in healthy men." Ther Drug Monit 11 (1989): 176-84. [PMID: 2718223]
45	Unge P, Svedberg LE, Nordgren A, et al. "A study of the interaction of omeprazole and warfarin in anticoagulated patients." Br J Clin Pharmacol 34 (1992): 509-12. [PMID: 1493083]
46	Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83. [PMID: 7944078]
47	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
48	Sommers DK, van Wyk M, Moncrieff J, Schoeman HS "Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil." Br J Clin Pharmacol 18 (1984): 535-9. [PMID: 6091711]
49	Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
50	Hughes GS, Heald DL, Barker KB, et al. "The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil." Clin Pharmacol Ther 46 (1989): 674-85. [PMID: 2557183]
51	Saathoff N, Lode H, Neider K, et al "Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist." Antimicrob Agents Chemother 36 (1992): 796-800. [PMID: 1354432]
52	Miura M, Tada H, Yasui-Furukori N, et al. "Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes." Chirality 17 (2005): 338-344. [PMID: 15856433]
53	Saito M, Yasui-Furukori N, Uno T, et al. "Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes." Br J Clin Pharmacol 59 (2005): 302-9. [PMID: 15752376]
54	Ushiama H, Echizen H, Nachi S, Ohnishi A "Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol." Clin Pharmacol Ther 72 (2002): 33-43. [PMID: 12152002]
55	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
56	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
57	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
58	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
59	Hutchison C, Geissler CA, Powell JJ, Bomford A "Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis." Gut 56 (2007): 1291-5. [PMID: 17344278]
60	Nand S, Tanvetyanon T "Proton pump inhibitors and iron deficiency: is the connection real?" South Med J 97 (2004): 799. [PMID: 15455957]
61	Product Information. Prilosec (omeprazole). Merck & Co, Inc, West Point, PA.
62	Sharma VR, Brannon MA, Carloss EA "Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia." South Med J 97 (2004): 887-9. [PMID: 15455980]
63	Stewart CA, Termanini B, Sutliff VE, et al "Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy." Aliment Pharmacol Ther 12 (1998): 83-98. [PMID: 9692706]
64	Product Information. Prilosec (omeprazole). Merck &amp Co, Inc, West Point, PA.
65	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
66	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
67	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
68	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
69	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
70	Cerner Multum, Inc. "Canadian Product Information.".
71	Product Information. Orkambi (ivacaftor-lumacaftor). Vertex Pharmaceuticals, Cambridge, MA.
72	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
73	Product Information. Synthroid (levothyroxine). Abbott Pharmaceutical, Abbott Park, IL.
74	Andersson T "Omeprazole drug interaction studies." Clin Pharmacokinet 21 (1991): 195-212. [PMID: 1764870]
75	Kiley CA, Cragin DJ, Roth BJ "Omeprazole-associated digoxin toxicity." South Med J 100 (2007): 400-2. [PMID: 17458401]
76	Le GH, Schaefer MG, Plowman BK, et al. "Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors." Am J Health Syst Pharm 60 (2003): 1343-5. [PMID: 12901036]
77	Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN "Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose." Br J Clin Pharmacol 32 (1991): 569-72. [PMID: 1954072]
78	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
79	Niwa T, Shiraga T, Takagi A "Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes." Biol Pharm Bull 28 (2005): 1805-8. [PMID: 16141567]
80	Zimmermann T, Yeates RA, Riedel KD, Lach P, Laufen H "The influence of gastric ph on the pharmacokinetics of fluconazole: the effect of omeprazole." Int J Clin Pharmacol Ther 32 (1994): 491-6. [PMID: 7820333]
81	Lu C, Berg C, Prakash SR, Lee FW, Balani SK "Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole." Drug Metab Dispos 36 (2008): 1261-6. [PMID: 18381488]
82	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
83	Product Information. Iressa (gefitinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
84	Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M "Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes." Eur J Clin Pharmacol 57 (2001): 709-15. [PMID: 11829200]
85	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
86	Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R "Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors." Ann Pharmacother 39 (2005): 162-4. [PMID: 15546944]
87	Burger DM, Hugen PWH, Kroon FP, Groeneveld P, Brinkman K, Foudraine NA, Sprenger H, Koopmans PP, Hekster YA "Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir." AIDS 12 (1998): 2080-2. [PMID: 9814882]
88	Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
89	Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6. [PMID: 6310994]
90	Chin TWF, Loeb M, Fong IW "Effects of an acidic beverage (coca-cola) on absorption of ketoconazole." Antimicrob Agents Chemother 39 (1995): 1671-5. [PMID: 7486898]
91	Jaruratanasirikul S, Sriwiriyajan S "Effect of omeprazole on the pharmacokinetics of itraconazole." Eur J Clin Pharmacol 54 (1998): 159-61. [PMID: 9626921]
92	Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ "Effects of ranitidine and sucralfate on ketoconazole bioavailability." Antimicrob Agents Chemother 35 (1991): 1765-71. [PMID: 1952845]
93	Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4. [PMID: 6253434]
94	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
95	Product Information. Naprosyn (naproxen). Syntex Laboratories Inc, Palo Alto, CA.
96	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
97	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
98	Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
99	Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ "Multicenter study of posaconazole therapeutic drug monitoring: exposure-response and factors affecting concentration." Antimicrob Agents Chemother 56 (2012): 5503-10. [PMID: 22890761]
100	Krishna G, Abutarif M, Xuan F, Martinho M, Angulo D, Cornely OA "Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome." Pharmacotherapy 28 (2008): 1223-32. [PMID: 18823218]
101	Krishna G, Moton A, Ma L, Medlock MM, McLeod J "The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers." Antimicrob Agents Chemother 53 (2009): 958-66. [PMID: 19075045]
102	Neubauer WC, Engelhardt M, Konig A, et al. "Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method." Antimicrob Agents Chemother 54 (2010): 4029-32. [PMID: 20547790]
103	Product Information. Noxafil (posaconazole). Schering-Plough Corporation, Kenilworth, NJ.
104	Shields RK, Clancy CJ, Vadnerkar A, et al "Posaconzaole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy." Antimicrob Agents Chemother 55 (2011): 1308-11. [PMID: 21189337]
105	Vaes M, Hites M, Cotton F, et al. "Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplasic syndrome." Antimicrob Agents Chemother 56 (2012): 6298-303. [PMID: 23027198]
106	Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P "Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations." Clin Pharmacokinet 50 (2011): 725-34. [PMID: 21973269]
107	Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J "Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole." 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20.
108	Product Information. Rifadin (rifampin). Hoechst Marion-Roussel Inc, Kansas City, MO.
109	Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
110	Inarrea P, Esteva F, Cornudella R, Lanas A "Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man." Scand J Gastroenterol 35 (2000): 242-6. [PMID: 10766315]
111	Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N "Interaction of omeprazole with enteric-coated salicylate tablets." Int J Clin Pharmacol Ther 36 (1998): 549-53. [PMID: 9799060]
112	Bradford GS, Taylor CT "Omeprazole and vitamin B-12 deficiency." Ann Pharmacother 33 (1999): 641-3. [PMID: 10369631]
113	Dutta SK "Vitamin b-12 malabsorption and omeprazole therapy." J Am Coll Nutr 13 (1994): 544-5. [PMID: 7706583]
114	Lavy NW "Omeprazole and vitamin B12." Ann Intern Med 121 (1994): 74. [PMID: 8198354]
115	Marcuard SP, Albernaz L, Khazanie PG "Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin-b12)." Ann Intern Med 120 (1994): 211-5. [PMID: 8273984]
116	Salom IL, Silvis SE, Doscherholmen A "Effect of cimetidine on the absorption of vitamin B12." Scand J Gastroenterol 17 (1982): 129-31. [PMID: 7134827]
117	Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
118	Product Information. Briviact (brivaracetam). UCB Pharma Inc, Smyrna, GA.
119	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
120	Product Information. Linzess (linaclotide). Forest Pharmaceuticals, St. Louis, MO.
121	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
122	Small DS, Farid NA, Payne CD, et al. "Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel." J Clin Pharmacol 48 (2008): 475-84. [PMID: 18303127]
123	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
124	Product Information. Erivedge (vismodegib). Genentech, South San Francisco, CA.
125	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
126	Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence